key: cord-0064802-olv0kulz authors: Rao, Vishal; Gulia, Ashish title: Convalescent plasma therapy in COVID-19: Does it merit a deeper probe? date: 2020-12-31 journal: Indian J Med Sci DOI: 10.25259/ijms_491_2020 sha: e9b8d7b3424f1643eb6684923162433eae6542f1 doc_id: 64802 cord_uid: olv0kulz nan In the methods of the PLACID trial, [5] details of nAb titers and IgG in the infused CP need to be clarified. The optimum titers play a pivotal role for the success of CPT; in the ICMR study, they have only mentioned that the titers were detectable but the % of high, moderate and low titers has not been mentioned. on the question of neutralizing antibody titers, IgG titers are typically associated with the severity of disease [8] and decline in the early convalescent phase [9] in less severe forms of the disease. In the PLACID trial, [5] most of the donors (94.2%) had mild disease. Moreover, the fact that antibody titers were not measured in CP before transfusion, due to lack of validated and reliable commercial tests for qualitative or quantitative antibody measurement, could be another key confounding factor. The heterogeneity of the PLACID trial [5] across its 39 study sites, especially in the severity of disease of enrolled participants, estimation of nAB (timing and method), and the "Standard of Care, " could impinge on the reliability of the study data. Variation in the antibody titers may result in heterogeneity in CP potency, and studies using conventional treatment as controls instead of placebo may complicate our evaluation of CPT efficacy. Although this has ethical implications, it may have a bearing on the statistical outcome. Further, in the ICMR study, [5] 67.9% of CPT group are PCR negative by day 7 when compared to 54.6% of non-CPT. This perhaps can be considered as beneficial impact of CPT which helps in decreasing community transmission. This data can also be used to tighten the discharge criteria to enable faster discharges, thus improving the availability of beds for a worsening pandemic. Notably, the dosage of CP administered is also variable. Some trials [10] are administering doses as high as 600 ml, in single infusions or divided doses, up to five transfusion sessions. The consensus about effective CP dose is yet to be elucidated. If we carefully examine the existing global preliminary data, they indicate a positive outcome of CPT for management of critically ill patients diagnosed with COVID-19. Hence, the need of the hour is to conduct further randomized controlled trials with larger sample sizes and homogeneity of data. Moreover, standardized diagnostic tools are required to evaluate the real efficacy of CPT in greater detail. The initial data of Mayo Clinic provides robust evidence that transfusion of convalescent plasma is safe in hospitalized COVID-19 patients and credibly supports the notion that early administration within the clinical course is more likely to reduce mortality. CPT can hence be safely used as an effective adjuvant therapy against COVID-19 associated mortality. Successful convalescent plasma therapy in a child with severe Coronavirus disease Emerging trends from COVID-19 research registered in the clinical trials registry-India Convalescent plasma transfusion therapy in severe COVID-19 patients-a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial Snapshot of COVID-19 related clinical trials in India Convalescent plasma in the management of moderate COVID-19 in adults in India: Open label phase II multicentre randomised controlled trial (PLACID Trial) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience, medRxiv SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections United Kingdom SARS-CoV-2 Convalescent Plasma Evaluation (SCoPE) Consortium. Convalescent plasma to treat critically ill patients with COVID-19: Framing the need for randomised clinical trials How to cite this article: Rao V, Gulia A. Convalescent plasma therapy in COVID-19: Does it merit a deeper probe?